Since the last CCSG renewal, Development Funds have supported 1) the recruitment of nine outstanding young investigators, 2) development of three new shared resources and a new service in an existing shared resource, and 3) partial funding for eight MD Anderson Multidisciplinary Research Program (MRP) awards, and three MD Anderson/Baylor Collaborative Multidisciplinary Research Projects. Some $435,000 of CCSG support for faculty recruitment has leveraged $4.5M in MD Anderson start-up packages and more than $11.6M in new extramural grants. MRP awards provide seed funding of $250,000 over 3 years for groups of three or more center members to support planning and development of cores and projects, and to obtain preliminary data for submission of an application for a P01, SPORE or CPRIT multi-investigator grant. Since the inception of MRP awards in 1997, MD Anderson has invested $7.6 million in these seed grants, associated with external peer-reviewed funding of more than $121 million, a 16-fold return on investment Since the last renewal, 8 proposals supported with $535,955 from CCSG Development Funds and matched approximately 2:1 with institutional funds, have leveraged $7,433,633 in peer-reviewed funding. Three Baylor/MD Anderson Collaborative MRPs supported with $92,518 in CCSG Development Funds resulted in a P01 award in 2011 of more than $13M over 5 years to Drs. E. Shall (MD Anderson) and C Bollard (Baylor) for their studies on improving cord blood transplantation in patients with cancer. Development funds supported establishing the Translational and Analytical Chemistry Core, the Characterized Cell Line Core, and the Functional Proteomics Reverse Phase Protein Array Core, which in aggregate have provided services to 273 center members and resulted in more than 200 publications. The Mutant Mouse Pathology Service has become part of the Research Animal Support Facility. In the current CCSG application. Development funds are requested to continue support for faculty recruitment and fund additional MRP awards. Support is also requested for three developing shared resources: the shRNA and Open Reading Frame Core, the High Throughput TALEN Engineering Core, and eHealth Technology. A competitive internal peer-review mechanism is also proposed for the allocation of Development Funds to provide support for establishing new methods and implementing new technologies within the shared resources.

Public Health Relevance

The budgetary flexibility afforded by the use of Development Funds facilitates strengthening of the cancer center through recruitment of outstanding new members, enables new technologies and shared resource services to be established, and enhances the competitiveness of applications for multi-investigator awards.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Daver, Naval; Verstovsek, Srdan (2015) Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma 56:279-80
Burstein, Matthew D; Tsimelzon, Anna; Poage, Graham M et al. (2015) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21:1688-98
Mersch, Jacqueline; Jackson, Michelle A; Park, Minjeong et al. (2015) Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121:269-75
Pugh, Thomas J; Mahmood, Usama; Swanson, David A et al. (2015) Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy 14:160-5
Zuo, Zhuang; Maiti, Sourindra; Hu, Shimin et al. (2015) Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol 28:373-82
Martin, Neil E; Massey, Laura; Stowell, Caleb et al. (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67:460-7
Shen, Qi; Ouyang, Juan; Tang, Guilin et al. (2015) Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol 95:168-76
Massarweh, Nader N; Haynes, Alex B; Chiang, Yi-Ju et al. (2015) Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough? Ann Surg 262:312-20
Garcia-Manero, Guillermo; Khoury, Hanna J; Jabbour, Elias et al. (2015) A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res 21:985-94
Brown, Alaina J; Sun, Charlotte C; Urbauer, Diana et al. (2015) Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer 23:2025-32

Showing the most recent 10 out of 2114 publications